Antiviral drugs are vital - but imperfect - tools for treatment and prevention of viral infections. Undesirable effects, from drug resistant viruses to low oral bioavailability, toxicity and severe side effects limit clinical usefulness. These factors drive demand for improved antiviral strategies. This book offers an up-to-date review of new drugs and targets, novel modes of action, vector-based treatments and even the blocking of defined genes by inhibiting mRNA formation (siRNA). Includes contributions by acknowledged experts; the book will serve as a compendium for R&D and educational professionals, and be of value for students.